 BrainsWay Ltd. NASDAQ TASE: BWAY BrainsWay, a global leader in the advanced non-invasive treatment of brain disorders, today announced that Dr. Christopher von Jako, Chief Executive Officer, will participate in the upcoming investor conferences. BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation Deep TMS technology for the treatment of major depressive disorder MDD and obsessive compulsive disorder OCD, for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration FDA in 2013 for MDD and in August 2018 for OCD. BrainsWay is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders. 